MBX Biosciences (MBX) Competitors $12.25 -0.11 (-0.89%) Closing price 04:00 PM EasternExtended Trading$12.24 -0.01 (-0.04%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MBX vs. EVO, IMCR, MESO, VERA, DYN, GPCR, ADPT, ANIP, SPRY, and CALTShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Evotec (EVO), Immunocore (IMCR), Mesoblast (MESO), Vera Therapeutics (VERA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Adaptive Biotechnologies (ADPT), ANI Pharmaceuticals (ANIP), ARS Pharmaceuticals (SPRY), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Evotec Immunocore Mesoblast Vera Therapeutics Dyne Therapeutics Structure Therapeutics Adaptive Biotechnologies ANI Pharmaceuticals ARS Pharmaceuticals Calliditas Therapeutics AB (publ) MBX Biosciences (NYSE:MBX) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings. Do analysts recommend MBX or EVO? MBX Biosciences currently has a consensus price target of $37.50, indicating a potential upside of 206.12%. Evotec has a consensus price target of $5.93, indicating a potential upside of 47.96%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Do insiders and institutionals hold more shares of MBX or EVO? 5.8% of Evotec shares are held by institutional investors. 52.2% of MBX Biosciences shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is MBX or EVO more profitable? Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A Evotec N/A N/A N/A Does the media prefer MBX or EVO? In the previous week, MBX Biosciences had 3 more articles in the media than Evotec. MarketBeat recorded 3 mentions for MBX Biosciences and 0 mentions for Evotec. MBX Biosciences' average media sentiment score of 1.17 beat Evotec's score of 1.08 indicating that MBX Biosciences is being referred to more favorably in the media. Company Overall Sentiment MBX Biosciences Positive Evotec Positive Which has preferable valuation and earnings, MBX or EVO? MBX Biosciences has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/AEvotec$788.22M1.81-$90.82MN/AN/A Does the MarketBeat Community favor MBX or EVO? MBX Biosciences and Evotec both received 7 outperform votes by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 53.85% of users gave Evotec an outperform vote. CompanyUnderperformOutperformMBX BiosciencesOutperform Votes7100.00% Underperform VotesNo VotesEvotecOutperform Votes753.85% Underperform Votes646.15% SummaryMBX Biosciences beats Evotec on 7 of the 9 factors compared between the two stocks. Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$409.44M$6.48B$5.35B$19.37BDividend YieldN/A2.66%5.22%3.84%P/E RatioN/A8.9226.8434.23Price / SalesN/A250.96391.3934.85Price / CashN/A65.8538.2517.51Price / BookN/A6.466.794.69Net IncomeN/A$143.98M$3.23B$1.02B7 Day Performance20.45%3.04%4.07%-1.34%1 Month Performance60.34%7.44%12.52%9.79%1 Year PerformanceN/A-2.46%16.83%3.27% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences2.9494 of 5 stars$12.25-0.9%$37.50+206.1%N/A$409.44MN/A0.0036News CoveragePositive NewsHigh Trading VolumeEVOEvotec1.4939 of 5 stars$4.17-3.0%$5.93+42.3%-21.9%$1.48B$788.22M0.004,200Gap DownIMCRImmunocore2.929 of 5 stars$29.54+4.0%$58.13+96.8%-39.1%$1.48B$310.20M-31.09320Positive NewsMESOMesoblast1.8344 of 5 stars$11.35+3.5%$18.00+58.6%+57.9%$1.45B$5.67M0.0080Gap DownVERAVera Therapeutics3.3651 of 5 stars$22.49+3.6%$63.33+181.6%-48.2%$1.43BN/A-8.6240Positive NewsDYNDyne Therapeutics3.7712 of 5 stars$12.56+10.1%$46.85+273.0%-65.1%$1.43BN/A-3.53100Positive NewsGap DownHigh Trading VolumeGPCRStructure Therapeutics2.1255 of 5 stars$24.62-3.7%$78.00+216.8%-31.1%$1.41BN/A-33.27136Gap UpADPTAdaptive Biotechnologies3.5631 of 5 stars$9.51+5.3%$9.83+3.4%+160.7%$1.37B$189.53M-8.72790News CoverageGap UpANIPANI Pharmaceuticals4.8288 of 5 stars$62.30-6.0%$80.13+28.6%-1.8%$1.36B$614.38M-113.27600High Trading VolumeSPRYARS Pharmaceuticals2.4345 of 5 stars$13.29-1.1%$31.00+133.3%+55.9%$1.31B$89.15M-26.0690Trending NewsEarnings ReportAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Evotec Competitors Immunocore Competitors Mesoblast Competitors Vera Therapeutics Competitors Dyne Therapeutics Competitors Structure Therapeutics Competitors Adaptive Biotechnologies Competitors ANI Pharmaceuticals Competitors ARS Pharmaceuticals Competitors Calliditas Therapeutics AB (publ) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MBX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBX Stock Free MBX Stock Alerts